Biotech Values

[10nisman]

And as I mentioned, the absent spectator to this whole affair is the TEVA shareholder. When TEVA's generic doesn't get approved and the stock continues to tank, TEVA shareholder lawyers might want to take more than a cursory look backwards at MNTA's complaint.

tLovenox (if approved) would not be material to Teva's results and thus Teva shareholder lawyers have no ground to stand-on.

IMO, the weakness in Teva's share price has nothing to do with the Sandoz/MNTA lawsuit (tLovenox) but more to do with horrible chart action driven by worries about Copaxone or some material matters (internal or pipeline) not yet disclosed.

10nis